3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Pathologic Complete Response
1
Leukemia, Myeloid, Acute
1
Interventions
Cytarabine
4
Azacitidine
3
sargramostim
2
cc-486
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Decitabine
2
venetoclax
1
thymoglobulin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
fludarabine phosphate
1
fludarabine
1
eltrombopag
1
Whole-Body Irradiation
1
Tacrolimus
1
Sulindac
1
Rituximab
1
Observation
1
Mycophenolic Acid
1
Methotrexate
1
Melphalan
1
Cyclophosphamide
1
Clofarabine
1
Busulfan
1
Bone Marrow Transplantation
1
Blood Specimen Collection
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Sulindac
×
Other hematologic neoplasm
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn